# Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)

> **NCT04397497** · PHASE2 · UNKNOWN · sponsor: **Ospedale San Raffaele** · enrollment: 50 (estimated)

## Conditions studied

- Covid-19
- Acute Respiratory Failure
- ARDS, Human
- Sars-CoV2
- Viral Pneumonia

## Interventions

- **DRUG:** Mavrilimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04397497
- **Lead sponsor:** Ospedale San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-22
- **Primary completion:** 2020-09-22
- **Final completion:** 2020-11-22
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04397497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04397497, "Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04397497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*